Elevance Health Inc. (NYSE: ELV) reported Q2 EPS of $7.45, $1.24 better than the analyst estimate of $6.21. Revenue for the quarter came in at $49.8 billion versus the consensus estimate of $48.63 billion.

GUIDANCE:

Elevance Health Inc. sees FY2026 EPS of at least $27.00, versus the consensus of $26.91.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.